← Russell 3000 cross-section

TMO THERMO FISHER SCIENTIFIC INC.

Trailing twelve months to 2026-06-27 · as filed 2026-07-31, not restated
Healthcare

Scale

Market cap
$234.1bn
Revenue TTM
$46.3bn
Net income TTM
$7.0bn
Free cash flow
$7.3bn
Composite score
46.1
Sector rank
#50

Valuation

P / E
33.6
EV / EBITDA
24.9
EV / sales
6.0
FCF yield
3.13%
Earnings yield vs 10-yr
-1.76pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
15.0%
EBITDA margin
23.9%
ROE
13.2%
ROIC
8.6%
Revenue growth
7.2%

Insider activity, last 90 days

Net open-market
$-59.02m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Consolidated Results Organic Revenue Growth During the second quarter of 2026, customer activity continued to strengthen across our end markets. Revenue growth was strong in the pharma and biotech market, with performance driven by strengthening underlying market conditions. Revenues in the academic and government market grew, and growth in the industrial and applied market was strong, both driven by customer demand for our innovative high-end instruments. Revenue to customers in the diagnostics and healthcare market was also strong. During the second quarter of 2026, sales increased across all major geographies. Revenue growth was strong in Europe and Asia-Pacific, including China. …THERMO FISHER SCIENTIFIC INC., 10-Q, period ended 2026-06-27, filed 2026-07-31

Read the full passage →